A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. by Kefford, R, Thomas, N, Corrie, P, Palmer, C, Abdi, E, Kotasek, D, Beith, J, Ranson, M, Mortimer, P, Watson, A, Margison, G, Middleton, MR

Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. by Ranson, M, Hersey, P, Thompson, D, Beith, J, McArthur, G, Haydon, A, Davis, I, Kefford, R, Mortimer, P, Harris, P, Baka, S, Seebaran, A, Sabharwal, A, Watson, A, Margison, G, Middleton, MR

O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. by Watson, A, Middleton, MR, McGown, G, Thorncroft, M, Ranson, M, Hersey, P, McArthur, G, Davis, I, Thomson, D, Beith, J, Haydon, A, Kefford, R, Lorigan, P, Mortimer, P, Sabharwal, A, Hayward, O, Margison, G

MicroRNA-related DNA repair/cell-cycle genes independently associated with relapse after radiation therapy for early breast cancer by Gee, H, Buffa, F, Harris, A, Toohey, J, Carroll, S, Cooper, C, Beith, J, McNeil, C, Carmalt, H, Mak, C, Warrier, S, Holliday, A, Selinger, C, Beckers, R, Kennedy, C, Graham, P, Swarbrick, A, Millar, E, O'Toole, S, Molloy, T